Is OCGN Worth Buying in 2026?

Ocugen, Inc. Common Stock

STOCK BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Updated 2026-06-07

Here’s whether Ocugen, Inc. Common Stock (OCGN) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.

🔴
Bearish

Positives: RSI 39 — healthy momentum range; strong 1-year return of +34.3%. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-9.68% over 10 days); 3-month momentum negative (-22.9%). Currently 53.0% off its 52-week high. Score: -3/7.

Ready to act on this? 📈 Trade on Webull

OCGN is trading below its 200-day MA ($1.52) — a key warning sign the longer-term trend is under pressure. An RSI of 39.2 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +34.3% compares to +24.4% for SPY (beat the market by 10.0%). The current 53.0% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.

$10,000 invested 1 year ago → $13,433 today
vs. S&P 500 (SPY) — same period beat market by 10.0%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

Above 200-day MA ($1.52)
Above 50-day MA ($1.61)
RSI(14) neutral zone (30–70) — currently 39.2
Positive return (+34.3%)
!Within 10% of period high (−53.0%)
Period Range $1.28
$0.90 $2.73
RSI (14) 39.2
0 · OversoldOverbought · 100

Key Metrics

Price$1.28
Period Return+34.3%
Period High$2.73
Period Low$0.90
Drawdown−53.0%
MA-50$1.61
MA-200$1.52
RSI (14)39.2
Avg Volume (30d)7.0M
vs. SPYbeat by 10.0%
Return Rank#449 of 1245

Trade OCGN

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers